Efficacy and safety of second-line agents for treatment of metastatic castration-resistant prostate cancer progressing after docetaxel. A systematic review and meta-analysis
Published: July 7, 2015
Abstract Views: 10424
PDF: 4347
SUPPLEMENTARY MATERIAL: 987
SUPPLEMENTARY MATERIAL: 987
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Perletti, G., Monti, E., Marras, E., Cleves, A., Magri, V., Trinchieri, A., & Rennie, P. S. (2015). Efficacy and safety of second-line agents for treatment of metastatic castration-resistant prostate cancer progressing after docetaxel. A systematic review and meta-analysis. Archivio Italiano Di Urologia E Andrologia, 87(2), 121–129. https://doi.org/10.4081/aiua.2015.2.121
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.